KLOW Protocol
Four-Peptide Regenerative Blend
KLOW builds upon GLOW protocol by adding KPV for enhanced anti-inflammatory action. This combination lacks clinical trials on the specific four-peptide formulation despite individual component research. Standard vial contains 80mg blend (50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, 10mg KPV).
Overview
KLOW builds upon GLOW protocol by adding KPV for enhanced anti-inflammatory action. This combination lacks clinical trials on the specific four-peptide formulation despite individual component research. Standard vial contains 80mg blend (50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, 10mg KPV).
Each peptide contributes distinct biological pathways: GHK-Cu modulates gene expression for tissue repair, TB-500 enhances cellular migration and wound healing, BPC-157 upregulates growth factors for tissue regeneration, and KPV inhibits NF-κB inflammatory pathway.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Multi-modal healing addressing tissue through complementary pathways
Enhanced tolerability with KPV versus GLOW formulation
Single injection convenience factor
Collagen stimulation and tissue regeneration
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Fixed-ratio peptide combination
- Typical dose
- 200-500 mcg total blend daily
- Frequency
- Once daily for consistent tissue repair support
- Cycle length
- 4-6 weeks
- Storage
- Lyophilized: Room temperature. Reconstituted: 2-8°C, use within 4-6 weeks
Molecular data
- Type
- Fixed-ratio peptide combination
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Conservative approach | Subcutaneous | 200mcg total daily | Once daily evening |
| Standard research protocol | Subcutaneous | 200-500mcg total | Once daily |
| Cycling protocol | Subcutaneous | Per standard dosing | 4-6 weeks on, 2-4 weeks off |
Interactions
KLOW contains all GLOW components plus KPV—combining causes double-dosing
No studies on combination; theoretical compatibility based on different mechanisms
No data combining KLOW with NAD+; both affect cellular processes differently
Components may affect wound healing and clotting—medical supervision required
Multiple components affect GH pathways; risk of excessive stimulation
Components may interfere with immunosuppressive therapy
Quality checklist
- ✓Third-party testing (Janoshik or similar)
- ✓Reputable research supplier with quality control
- ✓Certificate of Analysis provided
- !Research-only status - not approved for human use
- !Batch variability - ratios and purity may vary
- ×Vendors without Certificate of Analysis
- ×Suspiciously low prices suggest counterfeits
What to expect
Safety
- Injection site reactions (common even with KPV)
- Individual responses vary widely
- Severe injection site reactions or infection
- Allergic reactions (rash, difficulty breathing)
- Unusual fatigue or weakness
- Signs of copper toxicity (nausea, jaundice)
- Worsening of underlying conditions
- No safety studies on four-peptide combination
- Long-term effects completely unknown
- FDA has not approved any component for therapeutic use
FAQ
How is KLOW different from the GLOW protocol?
KLOW adds KPV to the GLOW formulation (GHK-Cu, TB-500, BPC-157). KPV provides additional anti-inflammatory benefits via NF-κB inhibition. The result is enhanced inflammation reduction with potentially fewer injection site reactions than GLOW alone. However, no clinical trials exist on this specific four-peptide combination.
Why do users get injection site reactions with KLOW?
GHK-Cu, the primary component (50mg/80mg), is a copper peptide that can be irritating locally. Even with KPV's anti-inflammatory properties, some users experience redness and swelling at injection sites. Rotating sites and using lower doses help mitigate reactions.
Can I use KLOW for surgical recovery?
Theoretically yes. The blend combines wound-healing (BPC-157, TB-500), anti-inflammatory (KPV, BPC-157), and tissue-regenerating (GHK-Cu) components. However, post-surgical use requires medical supervision due to effects on wound healing and clotting.
Is KLOW safe to use long-term?
Unknown. No clinical studies exist on four-peptide protocols, and long-term effects are completely unknown. Most users cycle 4-6 weeks on with 2-4 weeks off to minimize theoretical risks while allowing benefits to develop.
References
- 1Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growthStaresinic, M., et al. · Journal of Orthopaedic Research · 2003
Superior tendon healing with improved biomechanical properties (increased load of failure and Young's modulus), enhanced tendon-to-bone integration, and stimulated tendocyte growth in rat models.
in-vitroPubMed 14554208 ↗ - 2PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationDalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. · Gastroenterology · 2008
KPV inhibits NF-κB activation and reduces intestinal inflammation via PepT1-mediated transport; demonstrated anti-inflammatory effects in murine IBD models.
reviewPubMed 18061177 ↗ - 3Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene DataPickart, L., Margolina, A. · International Journal of Molecular Sciences · 2018
Broad regenerative potential demonstrated across skin, lung, bone, liver, and stomach tissue; cell protective actions including anti-cancer, anti-inflammatory, DNA repair, and proteasome activation via gene modulation.
reviewPubMed 29986520 ↗ - 4A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteersWang X, Liu L, Qi L, et al. · Journal of Cellular and Molecular Medicine · 2021
Phase I trial in 54 healthy subjects demonstrated recombinant thymosin β4 was well tolerated and safe across ascending IV doses up to 25 μg/kg with no significant accumulation.
human-rctPubMed 34346165 ↗